Physician profile
Samaha Syed
NPI 1881702587
$3,129.84
in general payments reported to CMS, 2019-2025
25 companies · $664 in 2025
The $664 reported for 2025 was more than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,063 · 2020: $748 · 2021: $83.69 · 2022: $109 · 2023: $94.10 · 2024: $369 · 2025: $664.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,125 · Education: $2.32.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,125.16 |
| Education | $2.32 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vifor Pharma, INC. | $373.94 | 2019-2022 | |
| Astrazeneca Pharmaceuticals LP | $364.18 | 2019-2025 | Farxiga, Lokelma |
| Amgen INC. | $353.05 | 2019-2025 | Krystexxa, Tavneos |
| Otsuka America Pharmaceutical, INC. | $267.74 | 2019-2024 | Jynarque |
| Horizon Therapeutics Plc | $266.89 | 2019-2023 | Krystexxa |
| Akebia Therapeutics INC | $202.89 | 2019-2022 | |
| Opko Pharmaceuticals, LLC | $163.98 | 2019-2025 | Rayaldee |
| Fresenius USA Marketing, INC. | $150.02 | 2019-2025 | Velphoro |
| Mallinckrodt Hospital Products INC. | $148.27 | 2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $120.67 | 2021-2025 | |
| Travere Therapeutics, INC. | $84.37 | 2023-2025 | |
| Mallinckrodt Enterprises LLC | $72.54 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $67.81 | 2024-2025 | Jardiance |
| Aurinia Pharma U.S., INC. | $61.91 | 2022-2024 | Lupkynis |
| Ardelyx, INC. | $60.29 | 2025 | Ibsrela |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alexion Pharmaceuticals, INC. | $54.40 | 2019 | |
| Novo Nordisk INC | $53.52 | 2025 | Ozempic, Rybelsus |
| Genentech USA, INC. | $52.80 | 2019-2020 | |
| Calliditas Therapeutics US INC. | $51.94 | 2025 | Tarpeyo |
| Janssen Pharmaceuticals, INC | $47.29 | 2019-2020 | |
| Shire North American Group INC | $34.18 | 2019 | |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $25.83 | 2024 | |
| Apellis Pharmaceuticals, INC. | $18.29 | 2025 | Empaveli |
| Glaxosmithkline, LLC. | $18.27 | 2024 | Benlysta |
| Smith+Nephew, INC. | $14.77 | 2024 | Oasis, Grafix Pl |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Samaha Syed listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.